The right partner masters complexity for biosimilar certainty.
Built on shared ownership clear governance, and aligned execution across the full biosimilar lifecycle.
Built for the long term.
Not the next milestone.
Shared ownership
Clear governance and shared ownership across every stage, from IND-enabling work through commercial supply.
Transparent communication
Responsive, direct communication and decision-making. No gaps, no delays between teams.
A model built to last
Designed for durability, speed, and long-term impact - not just the next milestone.
In-house leadership
Responsive, direct communication and decision-making. No gaps, no delays between teams.
We align on your program, design the right model together, and deliver.
Different program. Same structure.
Initiation
1.1
Molecule, stage, markets, timelines
1.2
Open conversation
1.3
We listen before we propose
Definition
2.1
Development plan, tailored to your program
2.2
Supply network, matched per program
2.3
Partnership model & conditions, defined upfront
Joint execution
3.1
From IND to commercial launch and beyond
3.2
One team, one point of accountability
3.3
We stay in - also post launch
The types of partners we are looking for
We partner selectively, across three roles, each governed under the same accountable system.
Commercial partners
Companies that bring approved biosimilars to their markets - licensing, distribution and launch.
Co-developers
Partners sharing development scope and risk, from molecule selection to regulatory filing.
Suppliers
CDMOs, CROs, and specialists chosen for fit, managed for consistency, integrated into one network.
Meet the team of experts behind every program
Deep expertise. Lean by intention.
Proven partnerships.
Global reach.
Biosimilar ranibizumab collaboration, origin licensed from Formycon AG.
Commercialization development, manufacturing, and supply for Natalizumab.
Out-licensing partnership for selected biosimilars across the Middle East & North Africa.
Commercialization for vedolizumab in territories outside MENA.
Commercialization for ocrelizumab biosimilar across LATAM but excluding Brazil.client (1-2 sentences)
Commercialization for ocrelizumab biosimilar in United States, Europe, Brazil, Canada, Australia, New Zealand, Israel and Turkey.
Let's build together.
If you want to explore what a partnership with us could look like, we're ready to talk.
